Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…Abstract Number: 0226 • ACR Convergence 2020
Similar Efficacy of Sarilumab Monotherapy (MONARCH) vs Sarilumab and Methotrexate Combination Therapy (MOBILITY B) in Patients with Rheumatoid Arthritis
Background/Purpose: Sarilumab, as monotherapy or in combination with conventional synthetic DMARDs like methotrexate (MTX) has demonstrated improvement in symptomatic and functional outcomes in patients (pts)…Abstract Number: 0882 • ACR Convergence 2020
Efficacy and Safety of Secukinumab in Patients with Spondyloarthritis and Enthesitis at the Achilles Tendon: 52-weeks Results from a Randomized, Placebo-controlled Phase 3b Trial
Background/Purpose: Enthesitis is a key feature of all types of spondyloarthritis (SpA) that substantially contributes to the overall burden of disease. Inhibition of the key…Abstract Number: 1329 • ACR Convergence 2020
Subclinical Atherosclerosis Risk in Psoriatic Arthritis: Could It Be Prevented?
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated inflammatory arthritis associated with psoriasis that can cause remarkable joint damage (1). Subclinical cardiovascular disease (CVD) due to…Abstract Number: 2025 • ACR Convergence 2020
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3…Abstract Number: 0232 • ACR Convergence 2020
Safety and Effectiveness of Tocilizumab in Patients with Renal Insufficiency in the Non-interventional Study ICHIBAN
Background/Purpose: RA increases a patient’s systemic inflammatory burden, which has been associated with development of chronic kidney disease (CKD), especially in patients with comorbid hypertension,…Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…Abstract Number: 1340 • ACR Convergence 2020
Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study
Background/Purpose: Patients with non-radiographic axial spondyloarthritis (nr-axSpA) suffer from comparable disease burden to patients with ankylosing spondylitis/radiographic axSpA (AS/r-axSpA), including inflammatory back pain, morning stiffness,…Abstract Number: 2027 • ACR Convergence 2020
Efficacy and Safety of Tildrakizumab, a High-Affinity Anti–Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study
Background/Purpose: Tildrakizumab (TIL), a high-affinity anti–interleukin-23p19 monoclonal antibody, is approved to treat moderate to severe plaque psoriasis.1 The efficacy and safety of TIL up to…Abstract Number: 1533 • 2012 ACR/ARHP Annual Meeting
Increased Circulating FoxP3+ T-Cells in Patients with Granulomatosis with Polyangiitis Are Attributed to an Increase in the Non-Suppressor FoxP3Low CD45RO+ TReg Cell Subpopulation
Background/Purpose: Human FoxP3+T-cells are functionally heterogeneous, and can be classified into three phenotypically distinct subpopulations based on the expression levels of FoxP3 and the memory…
- « Previous Page
- 1
- …
- 9
- 10
- 11